🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with estimates suggesting in excess of 82 million infections per year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This medication, which is employed against UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Data and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The study included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Having a single-dose, oral treatment such as this is seen as a "game-changer" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for patients and to halt the transmission of extremely resistant gonorrhoea globally.